FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200465604> ?p ?o ?g. }

• W4200465604 endingPage "e0261113" @default.
• W4200465604 startingPage "e0261113" @default.
• W4200465604 abstract "Background Complement activation contributes to lung dysfunction in coronavirus disease 2019 (COVID-19). We assessed whether C5 blockade with eculizumab could improve disease outcome. Methods In this single-centre, academic, unblinded study two 900 mg eculizumab doses were added-on standard therapy in ten COVID-19 patients admitted from February 2020 to April 2020 and receiving Continuous-Positive-Airway-Pressure (CPAP) ventilator support from ≤24 hours. We compared their outcomes with those of 65 contemporary similar controls. Primary outcome was respiratory rate at one week of ventilator support. Secondary outcomes included the combined endpoint of mortality and discharge with chronic complications. Results Baseline characteristics of eculizumab-treated patients and controls were similar. At baseline, sC5b-9 levels, ex vivo C5b-9 and thrombi deposition were increased. Ex vivo tests normalised in eculizumab-treated patients, but not in controls. In eculizumab-treated patients respiratory rate decreased from 26.8±7.3 breaths/min at baseline to 20.3±3.8 and 18.0±4.8 breaths/min at one and two weeks, respectively (p<0.05 for both), but did not change in controls. Between-group changes differed significantly at both time-points (p<0.01). Changes in respiratory rate correlated with concomitant changes in ex vivo C5b-9 deposits at one (rs = 0.706, p = 0.010) and two (rs = 0.751, p = 0.032) weeks. Over a median (IQR) period of 47.0 (14.0–121.0) days, four eculizumab-treated patients died or had chronic complications versus 52 controls [HR Crude (95% CI): 0.26 (0.09–0.72), p = 0.010]. Between-group difference was significant even after adjustment for age, sex and baseline serum creatinine [HR Adjusted (95% CI): 0.30 (0.10–0.84), p = 0.023]. Six patients and 13 controls were discharged without complications [HR Crude (95% CI): 2.88 (1.08–7.70), p = 0.035]. Eculizumab was tolerated well. The main study limitations were the relatively small sample size and the non-randomised design. Conclusions In patients with severe COVID-19, eculizumab safely improved respiratory dysfunction and decreased the combined endpoint of mortality and discharge with chronic complications. Findings need confirmation in randomised controlled trials." @default.
• W4200465604 created "2021-12-31" @default.
• W4200465604 creator A5013081757 @default.
• W4200465604 creator A5013451356 @default.
• W4200465604 creator A5019429551 @default.
• W4200465604 creator A5023372498 @default.
• W4200465604 creator A5036953057 @default.
• W4200465604 creator A5037825636 @default.
• W4200465604 creator A5040397073 @default.
• W4200465604 creator A5041554168 @default.
• W4200465604 creator A5045778675 @default.
• W4200465604 creator A5045918494 @default.
• W4200465604 creator A5048471035 @default.
• W4200465604 creator A5049831926 @default.
• W4200465604 creator A5052434587 @default.
• W4200465604 creator A5059276594 @default.
• W4200465604 creator A5059461770 @default.
• W4200465604 creator A5063740495 @default.
• W4200465604 creator A5064268922 @default.
• W4200465604 creator A5068937120 @default.
• W4200465604 creator A5076316519 @default.
• W4200465604 creator A5086275620 @default.
• W4200465604 creator A5090115261 @default.
• W4200465604 creator A5090926666 @default.
• W4200465604 date "2021-12-20" @default.
• W4200465604 modified "2023-10-18" @default.
• W4200465604 title "Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study" @default.
• W4200465604 cites W1499593166 @default.
• W4200465604 cites W1976386747 @default.
• W4200465604 cites W2023377972 @default.
• W4200465604 cites W2051293525 @default.
• W4200465604 cites W2123753762 @default.
• W4200465604 cites W2126092981 @default.
• W4200465604 cites W2169437650 @default.
• W4200465604 cites W2690246779 @default.
• W4200465604 cites W2780399380 @default.
• W4200465604 cites W2791501425 @default.
• W4200465604 cites W2806521568 @default.
• W4200465604 cites W2808166290 @default.
• W4200465604 cites W2898080189 @default.
• W4200465604 cites W2921315582 @default.
• W4200465604 cites W2942659049 @default.
• W4200465604 cites W3001118548 @default.
• W4200465604 cites W3004280078 @default.
• W4200465604 cites W3014294089 @default.
• W4200465604 cites W3016046582 @default.
• W4200465604 cites W3016123694 @default.
• W4200465604 cites W3019130299 @default.
• W4200465604 cites W3027964178 @default.
• W4200465604 cites W3032919298 @default.
• W4200465604 cites W3033762686 @default.
• W4200465604 cites W3035898754 @default.
• W4200465604 cites W3041160518 @default.
• W4200465604 cites W3082365904 @default.
• W4200465604 cites W3084100353 @default.
• W4200465604 cites W3096274861 @default.
• W4200465604 cites W3114184568 @default.
• W4200465604 cites W3157025007 @default.
• W4200465604 cites W3214252748 @default.
• W4200465604 cites W330731027 @default.
• W4200465604 doi "https://doi.org/10.1371/journal.pone.0261113" @default.
• W4200465604 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34928990" @default.
• W4200465604 hasPublicationYear "2021" @default.
• W4200465604 type Work @default.
• W4200465604 citedByCount "19" @default.
• W4200465604 countsByYear W42004656042022 @default.
• W4200465604 countsByYear W42004656042023 @default.
• W4200465604 crossrefType "journal-article" @default.
• W4200465604 hasAuthorship W4200465604A5013081757 @default.
• W4200465604 hasAuthorship W4200465604A5013451356 @default.
• W4200465604 hasAuthorship W4200465604A5019429551 @default.
• W4200465604 hasAuthorship W4200465604A5023372498 @default.
• W4200465604 hasAuthorship W4200465604A5036953057 @default.
• W4200465604 hasAuthorship W4200465604A5037825636 @default.
• W4200465604 hasAuthorship W4200465604A5040397073 @default.
• W4200465604 hasAuthorship W4200465604A5041554168 @default.
• W4200465604 hasAuthorship W4200465604A5045778675 @default.
• W4200465604 hasAuthorship W4200465604A5045918494 @default.
• W4200465604 hasAuthorship W4200465604A5048471035 @default.
• W4200465604 hasAuthorship W4200465604A5049831926 @default.
• W4200465604 hasAuthorship W4200465604A5052434587 @default.
• W4200465604 hasAuthorship W4200465604A5059276594 @default.
• W4200465604 hasAuthorship W4200465604A5059461770 @default.
• W4200465604 hasAuthorship W4200465604A5063740495 @default.
• W4200465604 hasAuthorship W4200465604A5064268922 @default.
• W4200465604 hasAuthorship W4200465604A5068937120 @default.
• W4200465604 hasAuthorship W4200465604A5076316519 @default.
• W4200465604 hasAuthorship W4200465604A5086275620 @default.
• W4200465604 hasAuthorship W4200465604A5090115261 @default.
• W4200465604 hasAuthorship W4200465604A5090926666 @default.
• W4200465604 hasBestOaLocation W42004656041 @default.
• W4200465604 hasConcept C111684460 @default.
• W4200465604 hasConcept C126322002 @default.
• W4200465604 hasConcept C141341695 @default.
• W4200465604 hasConcept C159654299 @default.
• W4200465604 hasConcept C167135981 @default.
• W4200465604 hasConcept C203014093 @default.
• W4200465604 hasConcept C203092338 @default.

• next